Treatment of Canine Pemphigus Foliaceus, Pemphigus Vulgaris and Mucous Membrane Pemphigoid With Oclacitinib: A Retrospective Analysis of 21 Cases
Veterinary Dermatology · 2026
DOI: 10.1111/vde.70078 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Veterinary Dermatology, 2026. Verfasst von Breanna L Scranton und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Wisconsin-Madison School of Veterinary Medicine, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Dog Diseases, Pemphigus, Sulfonamides, Pyrimidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
This study was performed to retrospectively evaluate the efficacy of oclacitinib (OC) (Apoquel; Zoetis) as a treatment option for pemphigus foliaceus (PF), pemphigus vulgaris (PV) and mucous membrane pemphigoid (MMP).
Objective
To determine if OC can reduce or replace the corticosteroid use in dogs with PF, PV and MMP. Animals There were no animal subjects. Procedure Multicentre retrospective study reviewing medical records from two institutions for dogs diagnosed with PF, PV or MMP and prescribed OC between 2014 and 2025.
Results
Twenty‐one dogs diagnosed with PF, PV or MMP via histopathological results were included. OC alone was effective in eight of 18 PF dogs at a median dose of 0.65 mg/kg/day per os (range 0.5–1.9 mg/kg/day p.o.). Five dogs reached clinical remission, and three reached partial remission. One PV dog and the MMP dog each reached clinical remission with OC alone at 0.7 mg/kg/day and 0.24 mg/kg every other day, respectively. OC was a corticosteroid‐sparing agent or adjunctive therapy in seven of 18 PF dogs at a median dose of 0.6 mg/kg/day (range 0.4–2.4 mg/kg/day). One PV dog reached partial remission at OC 1.9 mg/kg/day and prednisone 1.8 mg/kg/day yet died from pancreatitis. OC was ineffective in three of 18 PF dogs at a median dose of 1.0 mg/kg/day p.o. (range 0.9–1.2 mg/kg/day p.o.). Statistical significance was not analysed. Conclusions and Clinical Relevance OC is an effective sole therapeutic agent or adjunctive therapy in a subset of dogs with PF, PV or MMP. The long‐term safety of higher doses of OC is unknown.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Wisconsin-Madison School of Veterinary Medicine, Madison, Wisconsin, USA.
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, California, USA.
- Department of Pathology, Microbiology, Immunology, School of Veterinary Medicine, University California Davis, Davis, California, USA.
ORCID-Profile: Breanna L Scranton, Lara M Tomich, Andrea T H Lam, Verena K Affolter, Catherine A Outerbridge
Zitieren
APA
Scranton, B. L., Tomich, L. M., Lam, A. T. H., Affolter, V. K., & Outerbridge, C. A. (2026). Treatment of Canine Pemphigus Foliaceus, Pemphigus Vulgaris and Mucous Membrane Pemphigoid With Oclacitinib: A Retrospective Analysis of 21 Cases. Veterinary Dermatology. https://doi.org/10.1111/vde.70078
Vancouver
Scranton BL, Tomich LM, Lam ATH, Affolter VK, Outerbridge CA. Treatment of Canine Pemphigus Foliaceus, Pemphigus Vulgaris and Mucous Membrane Pemphigoid With Oclacitinib: A Retrospective Analysis of 21 Cases. Veterinary Dermatology. 2026. doi:10.1111/vde.70078
BibTeX
@article{Scranton2026,
author = {Scranton, Breanna L and Tomich, Lara M and Lam, Andrea T H and Affolter, Verena K and Outerbridge, Catherine A},
title = {Treatment of Canine Pemphigus Foliaceus, Pemphigus Vulgaris and Mucous Membrane Pemphigoid With Oclacitinib: A Retrospective Analysis of 21 Cases},
journal = {Veterinary Dermatology},
year = {2026},
doi = {10.1111/vde.70078}
}
EUVIMED